The Molecular Imaging Research of F-18 Labeled DX600 PET Probe

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037886

Enrollment

Unknown

Registered

2020-09-03

Start date

2020-09-07

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

3 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patients aged more than 3 years are not limited to men and women; 2. Patients with ECoG score 0 or 1; 3. Subjects with high expression of ACE2 in colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain tumor and other tumors with high expression of ACE2 in the near future (within 2 months); 4. 18F-FDG PET / CT results were used as baseline evaluation.

Exclusion criteria

Exclusion criteria: 1. Patients with severe abnormal liver and kidney function; 2. Pregnant and lactating women preparing for pregnancy; 3. Patients who cannot lie on their back for half an hour; 4. Patients with claustrophobia or other mental disorders; 5. Patients who refuse to join this clinical study.

Design outcomes

Primary

Measure	Time frame
SUVmax;	—

Countries

China

Contacts

Public ContactZhu Hua

Cancer Hospital of Peking University

zhuhuabch@pku.edu.cn+86 10-88196495

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026